萬基遺傳 MYGN 深 滬
交易中 04-01 11:23:58 美东时间
4.685
+0.185
+4.11%
華盛通- 最 高4.695
- 今 開4.53
- 成交量 24.39万股
- 最 低 4.51
- 昨 收 4.50
- 總市值 4.38亿
- 52周最高 8.59
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 3.76
- 委 比 -3.41%
- 總股本 9350.82万
- 歷史最高 50.44
- 量 比 0.73
- 振 幅 4.11%
- 歷史最低 3.76
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Myriad Genetics Gets FDA Approval Of MyChoice CDx Test As Companion Diagnostic For Zejula, PARP Inhibitor From GSK, For Patients With Advanced Ovarian Cancer
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the
03-18 04:12
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
<p>Myriad Genetics announced the FDA approval of its MyChoice CDx Test as a companion diagnostic for GSK's Zejula, a PARP inhibitor for advanced ovarian cancer patients. This approval establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S. The test identifies HRD-positive patients using next-generation sequencing to assess BRCA1/2 genes and tumor genomic instability, helping guide precise treatment decisions....
03-17 20:05
Veracyte Appoints Kevin Haas as Chief Technology Leader
Veracyte ( ($VCYT) ) just unveiled an update. On March 16, 2026, Veracyte, Inc....
03-17 04:57
万基遗传2025财年营收8.18-8.28亿美元，毛利率显著提升
经济观察网 2026年3月6日国际罕见病日期间发布的《2026罕见病行业趋势观察报告》指出，我国罕见病诊疗体系已实现全面升级，平均确诊时间从4年缩短至4周，2...
03-13 00:43
万基遗传AI商业化前景分析：技术应用与行业竞争并存
经济观察网 根据截至2026年3月3日的公开信息，万基遗传（MYGN）的AI商业化前景主要体现在其技术应用、业务规划及行业环境之中。 业务进展情况 公司正通过...
03-03 05:17
Myriad Commercially Launches Precise MRD with Select Community Oncologists
<p>Myriad Genetics announced the launch of the Precise MRD test for breast cancer patients, enabling earlier detection of residual cancer cells through ultrasensitive ctDNA检测. The test uses whole-genome sequencing to create personalized panels for monitoring treatment efficacy. Initially available to select oncology practices, Myriad plans a broader U.S. launch later this year.</p>
03-02 21:05
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $6
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $8 to $6.
02-25 03:20
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
